Axonal transection in the lesions of multiple sclerosis.

BACKGROUND Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system and is the most common cause of neurologic disability in young adults. Despite antiinflammatory or immunosuppressive therapy, most patients have progressive neurologic deterioration that may reflect axonal loss. We conducted pathological studies of brain tissues to define the changes in axons in patients with multiple sclerosis. METHODS Brain tissue was obtained at autopsy from 11 patients with multiple sclerosis and 4 subjects without brain disease. Fourteen active multiple-sclerosis lesions, 33 chronic active lesions, and samples of normal-appearing white matter were examined for demyelination, inflammation, and axonal pathologic changes by immunohistochemistry and confocal microscopy. Axonal transection, identified by the presence of terminal axonal ovoids, was detected in all 47 lesions and quantified in 18 lesions. RESULTS Transected axons were a consistent feature of the lesions of multiple sclerosis, and their frequency was related to the degree of inflammation within the lesion. The number of transected axons per cubic millimeter of tissue averaged 11,236 in active lesions, 3138 at the hypocellular edges of chronic active lesions, 875 in the hypocellular centers of chronic active lesions, and less than 1 in normal-appearing white matter from the control brains. CONCLUSIONS Transected axons are common in the lesions of multiple sclerosis, and axonal transection may be the pathologic correlate of the irreversible neurologic impairment in this disease.

[1]  M. Bornstein,et al.  Functional Studies of Cultured Brain Tissues as Related to "Demyelinative Disorders" , 1965, Science.

[2]  W. Norton,et al.  MYELINATION IN RAT BRAIN: METHOD OF MYELIN ISOLATION 1 , 1973, Journal of neurochemistry.

[3]  R. Lasek,et al.  The slow component of axonal transport. Identification of major structural polypeptides of the axon and their generality among mammalian neurons , 1975, The Journal of cell biology.

[4]  I. A. Boyd,et al.  Ultrastructural dimensions of myelinated peripheral nerve fibres in the cat and their relation to conduction velocity , 1980, The Journal of physiology.

[5]  J. Prineas,et al.  Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown , 1981, Annals of neurology.

[6]  L. Sternberger,et al.  Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[7]  N. Hirokawa,et al.  Organization of mammalian neurofilament polypeptides within the neuronal cytoskeleton , 1984, Journal of Cell Biology.

[8]  E. Cho,et al.  Continual Breakdown and Regeneration of Myelin in Progressive Multiple Sclerosis Plaques a , 1984, Annals of the New York Academy of Sciences.

[9]  A. Windebank,et al.  Myelination determines the caliber of dorsal root ganglion neurons in culture , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[10]  J. Trojanowski,et al.  Novel monoclonal antibodies provide evidence for the in situ existence of a nonphosphorylated form of the largest neurofilament subunit , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  J. Trojanowski,et al.  Monoclonal antibodies distinguish several differentially phosphorylated states of the two largest rat neurofilament subunits (NF-H and NF-M) and demonstrate their existence in the normal nervous system of adult rats , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[12]  R. Newcombe,et al.  A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[13]  B. Trapp,et al.  The myelin-associated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes , 1989, The Journal of cell biology.

[14]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[15]  A. Cross,et al.  Axonal dystrophy as a consequence of long-term demyelination. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[16]  B Bacci,et al.  Amyloid precursor protein and ubiquitin immunoreactivity in dystrophic axons is not unique to Alzheimer's disease. , 1991, The American journal of pathology.

[17]  C. Brosnan,et al.  Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. , 1991, The Journal of clinical investigation.

[18]  T. Kitamoto,et al.  Alzheimer's amyloid precursor protein accumulates within axonal swellings in human brain lesions , 1992, Neuroscience Letters.

[19]  Scott T. Brady,et al.  Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells , 1992, Cell.

[20]  Roland Martin,et al.  Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.

[21]  D. Graham,et al.  β-Amyloid precursor protein (βAPP) as a marker for axonal injury after head injury , 1993, Neuroscience Letters.

[22]  D. Hanley,et al.  Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains , 1994, Annals of neurology.

[23]  G J Barker,et al.  Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.

[24]  B. Trapp,et al.  Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions , 1994, Journal of Neuroimmunology.

[25]  W. Mcdonald RACHELLE FISHMAN-MATTHEW MOORE LECTURE: The Pathological and Clinical Dynamics of Multiple Sclerosis , 1994, Journal of neuropathology and experimental neurology.

[26]  P. Matthews,et al.  Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis , 1994, Annals of neurology.

[27]  A. Thompson,et al.  Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. , 1995, Brain : a journal of neurology.

[28]  P. Matthews,et al.  Reversible decreases in N‐acetylaspartate after acute brain injury , 1995, Magnetic resonance in medicine.

[29]  N. Hirokawa,et al.  Two distinct functions of the carboxyl-terminal tail domain of NF-M upon neurofilament assembly: cross-bridge formation and longitudinal elongation of filaments , 1995, The Journal of cell biology.

[30]  M. Schachner,et al.  Crucial Role for the Myelin‐associated Glycoprotein in the Maintenance of Axon‐Myelin Integrity , 1995, The European journal of neuroscience.

[31]  P. Matthews,et al.  Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.

[32]  M. Namboodiri,et al.  N-acetylaspartate as an acetyl source in the nervous system. , 1995, Brain research. Molecular brain research.

[33]  A J Thompson,et al.  Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.

[34]  J. Haines,et al.  A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex , 1996, Nature Genetics.

[35]  P. Goodfellow,et al.  A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 , 1996, Nature Genetics.

[36]  P M Matthews,et al.  Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.

[37]  R. Nixon,et al.  Oligodendroglia Regulate the Regional Expansion of Axon Caliber and Local Accumulation of Neurofilaments during Development Independently of Myelin Formation , 1996, The Journal of Neuroscience.

[38]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[39]  D. Hinds,et al.  A full genome search in multiple sclerosis , 1996, Nature Genetics.

[40]  B. Trapp,et al.  Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. , 1996, Journal of neuropathology and experimental neurology.

[41]  B. Weinshenker,et al.  Epidemiology of multiple sclerosis. , 1996, Neurologic clinics.

[42]  A. Thompson,et al.  Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. , 1996, Brain : a journal of neurology.

[43]  B. Trapp,et al.  Differentiation and Death of Premyelinating Oligodendrocytes in Developing Rodent Brain , 1997, The Journal of cell biology.

[44]  R. Hohlfeld,et al.  Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. , 1997, Brain : a journal of neurology.

[45]  P. Matthews,et al.  Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions , 1997, Annals of neurology.

[46]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.